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Objectives. We sought o determine the response rate and safety 
of intravenous amiodarone in patients with ventricular tachy- 
arrhythmias refractory to standard therapies. 
Background. Numerous mall retrospective r ports suggest a 
response of refractory ventricular tachyarrhythmias to intrave- 
nous amiodarone, yet no controlled prospective trials exist. 
Methods. Two hundred seventy-three patients with recurrent 
hypotensive ventricular tachyarrhythmias refractory to lidocaine, 
procainamide and bretylium were randomized to receive one of 
three doses of intravenous amiodarone: 525, 1,050 or 2,100 rag/24 h 
(mean [-+SE] dose 743.7 -+ 418.7, 1,175.2 -+ 483.7, 1,921.2 -+ 
688.8 mg, respectively) by continuous infusion over 24 h. 
Results. Of the 273 patients, 110 (40.3% response rate) survived 
24 h without another hypotensive ventricular tachyarrhythmic 
event while being treated with intravenous amiodarone as a single 
agent (primary end point). A significant difference in the time to 
first recurrence of ventricular tachyarrhythmia (post hoc analy- 
sis) over the first 12 h was observed when the combined 1,050- and 
2,100-rag dose groups were compared with the 525-mg dose group 
(p = 0.046). The number of supplemental (150 rag) infusions of 
intravenous amiodarone (given for breakthrough destabilizing 
tachyarrhythmias) during hours 0 to 6 (prespecified secondary 
end point) was significantly greater in the 525-mg dose group than 
in the 2,100-mg dose group (1.09 + 1.57 vs. 0.51 -+ 0.97, p = 
0.0043). However, there was no clear dose-response r lation 
observed in this trial with respect o success rates (primary end 
point), time to first recurrence of tachyarrhythmia (post hoc 
analysis) or mortality (secondary end point) over 24 h. 
Conclusions. Intravenous amiodarone is a relatively safe ther- 
apy for ventricular tachyarrhythmias refractory to other medica- 
tions. 
(J Am Coil Cardiol 1996;27:67-75) 
Amiodarone is associated with a significant antiarrhythmic 
effect, even in patients with refractory ventricular arrhythmias 
(1-5). Because it has a relatively slow onset of action when 
administered orally, maximal effect is not reached until 2 to 4 
weeks after the initiation of therapy despite aggressive oral 
loading (6). In contrast, intravenous administration has a rapid 
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antiarrhythmic effect in patients with recurrent, sustained 
ventricular tachyarrhythmias (7-11). 
Previously published reports of intravenous amiodarone 
have been either retrospective r views or the results of uncon- 
trolled studies with relatively small numbers of patients who 
were often treated concomitantly with other antiarrhythmic 
medications. Therefore, the present prospective, controlled, 
randomized, double-blind, dose-range study was undertaken to 
determine definitively the response to intravenous amiodarone 
(Cordarone Intravenous, Wyeth-Ayerst Research, Radnor, 
Pennsylvania) in patients with life-threatening ventricular ar- 
rhythmias. 
Methods  
Patient selection. A total of 273 patients with sustained 
hypotensive ventricular tachycardia or fibrillation refractory to 
standard therapy were enrolled in this study at 39 medical 
centers in the United States. Hypotensive ntricular tachycar- 
dia was defined as ventricular tachycardia causing systolic 
blood pressure to decrease <80 mm Hg with clinical signs or 
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Table 1. Baseline Clinical Characteristics 
Amiodarone Dose Group 
500 mg 1,000 mg 2,000 mg Total 
(n = 88) (n = 92) (n = 93) (n = 273) 
Male 61 (69) 67 (73) 70 (75) 198 (73) 
Female 27 (31) 25 (27) 23 (25) 75 (27) 
Age (yr) 63 ~ 10 63 + 12 63 _+ 11 63 --- 11 
LVEF (%) 33 + 14 31 _+ 12 33 _+ 16 32 + 14 
NYHA functional class 
I/II 29 (45) 29 (42) 30 (46) 88 (44) 
III 17 (27) 16 (23) 17 (26) 50 (25) 
IV 18 (28) 24 (35) 18 (28) 60 (30) 
Presenting arrhythmia 
VF 6 (7) 4 (4) 5 (5) 15 (5) 
Incessant VT 22 (25) 32 (35) 27 (29) 81 (30) 
HDVT 60 (68) 56 (61) 61 (66) 177 (65) 
Cardiac substrate* 
Coronary disease 78 (89) 78 (85) 80 (86) 236 (86) 
Cardiomyopathy 15 (20) 24 (27) 23 (25) 62 (23) 
Valvular disease 25 (28) 26 (28) 31 (33) 82 (30) 
*Somc patients had more than one cardiac diagnosis. Data presented are 
mean value _+ SD or number (%) of patients. HDVT - hemodynamically 
destabilizing ventricular tachycardia; LVEF = left ventricular ejection fraction; 
NYHA = New York Heart Association; VF - ventricular fibrillation; VT = 
ventricular tachycardia. 
symptoms of shock. The baseline and demographic character- 
istics of these patients are summarized inTable 1. There were 
no significant differences in any variable among dose groups at 
baseline. All patients had at least two episodes (mean 5.9) of 
hypotensive ventricular tachyarrhythmias in the 24 h before 
admission or were in incessant ventricular tachycardia, despite 
attempts at cardioversion. Cardioversion was required to ter- 
minate these events in >80% of the episodes; 15% required 
cardiopulmonary resuscitation; 51% resulted in loss of con- 
sciousness. 
All patients included were refractory to (therapy failed, 
with breakthrough ventricular tachyarrhythmias) or intolerant 
of (limited by side effects) the standard oses of lidocaine (or 
oral mexiletine or tocainide), intravenous ororal procainamide 
and bretylium within the 72 h before blinded intravenous 
amiodarone administration was instituted. Patients were ex- 
cluded if they were in cardiogenic shock (unrelated to their 
arrhythmia) or had significant hepatic dysfunction, chronic 
pulmonary disease, acute pulmonary edema or respiratory 
failure. Patients were also excluded if they had a history of 
torsade de pointes, congenital QT prolongation, sick sinus 
syndrome, sinus arrest, symptomatic bradycardia, sinoatrial 
block or second-degree or higher atrioventricular block (unless 
they had a pacemaker). All patients had systolic blood pressure 
>90 mm Hg (except during ventricular tachycardia or fibrilla- 
tion), heart rate >50 beats/rain, QT interval <0.55 s and 
arterial pH >7.25. 
Institutional review board approval was obtained, and all 
patients gave written informed consent when possible; awaiver 
of informed consent was obtained before the study for patients 
who were unable to provide consent. 
Table 2. Double-Blind Dosage Regimen 
Amiodarone Dose Group and 
Infusion Period Infusion Rate 
500 rag/24 h 
Initial rapid 75 mg over 10 min 
Loading 0.50 mg/min (0-6 h) 
Maintenance 0.25 mg/min (6-24 h) 
1,000 m~/24 h 
Initial rapid 150 mg over 10 min 
Loading 1.0 mg/min (0-6 h) 
Maintenance 0.5 rag/rain (6-24 h) 
2,000 mg/24 h 
Initial rapid 300 mg over 10 rain 
Loading 2.0 mg/min (0-6 h) 
Maintenance 1.0 mg/min (6-24 h) 
Study protocol. Patients were treated in areas with facili- 
ties for continuous monitoring and administration f advanced 
cardiac life support. Because a placebo treatment group was 
deemed by the investigators to be unethical, a dose-response 
study comparing three blinded dose regimens of intravenous 
amiodarone was instituted. Patients were randomly assigned to 
a dose regimen that delivered 525, 1,050 or 2,100 mg over 24 h. 
For convenience of expression, these dose regimens will be 
referred to subsequently asthe 500-, 1,000- and 2,000-mg dose 
groups. 
As shown in Table 2, each patient received an initial rapid 
infusion over 10 rain, followed by a 6-h loading infusion and 
then a maintenance infusion from hours 6 to 24 of the study. 
Additional open-label supplemental infusions (150 mg over 
10 rain) of intravenous amiodarone were permitted for the 
treatment ofbreakthrough episodes of hypotensive ventricular 
tachycardia or fibrillation during the loading infusion (hours 0 
to 6). Breakthrough arrhythmia was defined as an episode of 
hypotensive ventricular tachycardia or fibrillation requiring 
intervention. Therapy was considered a failure in patients with 
hypotensive ventricular tachycardia orfibrillation after hour 6. 
Blinded therapy was therefore discontinued. 
During double-blind intravenous amiodarone therapy, the 
use of other antiarrhythmic medications for treatment of 
ventricular arrhythmias was not permitted; other concomitant 
drug therapies were allowed. After discontinuation f blinded 
therapy, openqabel intravenous amiodarone therapy (includ- 
ing the additional 150-mg supplemental infusions) or other 
antiarrhythmic therapy could be instituted at the investigator's 
discretion. 
Assessment of response to intravenous amiodarone. The 
primary end point was the proportion of patients who survived 
with a successful response defined as no further episodes of 
hemodynamically destabilizing ventricular tachycardia orven- 
tricular fibrillation and no adverse xperiences requiring dis- 
continuation of the drug during hours 6 to 24 of the double- 
blind period (Fig. 1). Secondary analyses of response during 
the 24-h double-blind phase included survival during the first 
24 h, successful therapy as a function of left ventricular ejection 
fraction and as a function of underlying cardiac disease process 
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No breakthrough HDVT or VF 
during maintenance infusion 
(6 - 24 hrs) 
Figure 1. Study flowchart. Patients were 
randomly assigned toone of three doses 
of intravenous amiodarone. HDVT = 
hemodynamically destabilizing ventricu- 
lar tachycardia; VF = ventricular fibril- 
lation. 
~ ' /  Loading | I Maintenance | 1000 rag/24 hrs l~  Infusion H Infusion 
2000 rag/Z4 hrs ~--  
/ 
Failure 
BREAKTHROUGH HDVT or VF 
during maintenance infusion 
(6 - 24 hrs) 
or 
Multiple HDVT or VF 
(0 - 6 hrs) 
or 
Severe Adverse Effects 
(0 - 24 hrs) 
as well as the number of additional boluses of intravenous 
amiodarone given during the first 6 h. Other analyses, added 
post hoc after completion of enrollment, were time to first 
hemodynamically destabilizing ventricular tachycardia orven- 
tricular fibrillation event and cumulative dose (total, double- 
blind and supplemental doses). Other post hoc analyses in- 
cluded number of supplemental boluses given in the first 24 h, 
time to first event, proportion of patients requiring supplemen- 
tal infusions and dose of supplemental infusions. Proarrhyth- 
mia, as defined by torsade de pointes or spontaneous new 
ventricular fibrillation, and breakthrough sustained hypoten- 
sive ventricular tachycardia/fibrillation were considered pri- 
mary end points for failure of therapy. The primary and 
secondary end points were defined at the start of the study, 
whereas other analyses were added on an ad hoc basis after 
completion of the protocol patient entry phase. 
Safety assessments. Cardiac examinations were performed 
daily for 10 days, at week 2 and at months 1, 2 and 3. 
Continuous electrocardiographic (ECG) telemetry was used 
during intravenous amiodarone therapy. Systolic blood pres- 
sure and heart rate measurements were obtained every 15 min 
to hour 6, every hour during hours 6 to 24 and then every 4 h 
during subsequent intravenous therapy. Adverse effects were 
recorded throughout the study. Because of the dflticulty of 
determining whether ecurrent intractable ventricular tachy- 
cardia or fibrillation represents a lack of response or proar- 
rhythmia in these patients, many of whom were referred for 
enrollment under emergent circumstances, proarrhythmia w s 
prospectively defined as episodes of torsade de pointes or 
spontaneous new-onset ventricular fibrillation (excluding ven- 
tricular tachycardia that degenerated into ventricular fibrilla- 
tion). Clinical laboratory tests were evaluated at hour 24; on 
days 3, 5, 7 and 10; at week 2; and at months 1, 2 and 3. These 
tests included complete blood counts, serum chemical analyses 
with liver, renal, and thyroid profiles and electrolyte l vels. A 
12-lead ECG was recorded at hours 6, 12 and 24; on days 2, 3, 
5, 7 and 10; at week 2; and at months 1, 2 and 3. 
Statistical methods. Once assigned to a treatment group, 
patients were included in the intention-to-treat analysis. The 
double-blind period started at the first administration of 
amiodarone. 
The overall response rate, the primary end point, was 
analyzed in patients who completed the loading infusion 
(hours 0 to 6). Only hypotensive ventricular tachycardia or 
fibrillation event data collected after the loading infusion were 
analyzed. Treatment was considered ineffective inpatients with 
one or more episodes of hypotensive ventricular tachycardia or
fibrillation during hours 6 to 24 or those not completing the full 
24-h double-blind period. In the present analysis, treatment 
was not considered a failure in any patient who had recurrent 
arrhythmias, died or was withdrawn during the loading infu- 
sion; rather, these patients were considered ineligible for the 
response analysis. Treatment was also considered a failure in 
patients withdrawn from the trial before hour 6. 
Although not protocol specified, the time to first hemody- 
namically destabilizing ventricular tachycardia or ventricular 
fibrillation event was analyzed in all patients who completed 
the initial infusion, regardless of whether they completed the 
entire 24-h double-blind period. In most cases, this time was 
calculated from the end of the initial infusion (minute 10). 
Events that occurred before the initial infusion was completed 
were excluded from analysis unless the event overlapped the 
end of the infusion; in these cases, the time to first hypotensive 
tachyarrhythmic event was calculated from the end of that 
event. 
Initially, either an overall test of differences among treat- 
ment groups or a linear trend test was performed for each 
variable. All tests were two-tailed and performed at the 0.05 
level of significance. The results of the paired comparisons 
were considered descriptive statistics not requiring correction 
for multiplicity and were displayed only for tests resulting in a 
strong tendency (p < 0.10). 
The proportion of patients with successful response was 
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Table 3. Response to Therapy by Dose Group 
Amiodarone Dose Group 
Combined 1,000 
500 mg 1,000 mg 2,000 mg and 2,000 mg 
End Point (n = 86) (n = 92) (n = 92) (n = 184) 
p Value 
(log-rank test) 
No. of pts with successful response 78 80 79 
6-24 h [no. (%)] 32 (41%) 36 (45%) 42 (53%) 
Median time to 1st event 
0-24 h 4.8 14.6 10.5 14.6 
0-12 h 4.8 >12 
0.298 
0.305,* 0.134t 
0.046 
*500 mg versus 1,000 mg versus 2,000 mg. t500 mg versus 1,000 and 2,000 mg combined, pts patients. 
analyzed by the chi-square test to examine differences among 
dose groups. In addition, a test for trend (Mantel-Haenszel 
chi-square statistic) was done to determine whether there was 
a linear dose-response r lation. 
The Cochran-Mantel-Haenszel procedure was used to test 
for an association between the dose groups and the dose- 
response after adjusting for the influence of several prognostic 
variables. These variables included underlying cardiac disease, 
presenting arrhythmia and degree of left ventricular ejection 
fraction. 
The log-rank test was used to test for trends across dose 
groups for the time to first hypotensive ventricular tachycardia 
or fibrillation event and for survival time. Hourly summaries of 
the product-limit (Kaplan-Meier) survival estimates were used 
to represent these data graphically. The log-rank test and 
product-limit survival estimates censored patients who with- 
drew before hour 24 or who completed 24 h without an event. 
Analysis of variance was used to test for differences among 
dose groups in cumulative total dose, cumulative double-blind 
dose and cumulative supplemental intravenous boluses. Dose 
data were log(x + 1) transformed before analysis. 
Results 
One hundred ten (46%) of the 237 patients who completed the 
6-h loading infusion survived the 6- to 24-h maintenance 
period without a recurrence of hypotensive ventricular tachy- 
cardia or fibrillation when intravenous amiodarone was used as 
a single agent. Another 29 patients (12%) responded to 
intravenous amiodarone in combination with another agent. A 
total of 36 patients (15%) were withdrawn from blinded 
intravenous amiodarone therapy during the first 6 h; 17 (7%) 
died; 14 (6%) were withdrawn due to adverse ffects; and 5 
(2%) were withdrawn because of intractable ventricular 
tachyarrhythmias. Of those patients whose arrhythmias were 
not controlled by intravenous amiodarone in the 6- to 24-h 
time frame, 14 (5%) died and 7 (3%) were withdrawn from 
therapy because of adverse ffects. 
Dose-response. There was a numerical trend observed in 
the primary end point response rate, with increased response 
at higher doses (41%, 45% and 53% for the low, medium and 
high dose groups, respectively). However, this numerical trend 
did not reach statistical significance (p = 0.298). The results of 
this analysis are shown in Table 3. 
As with the overall response rate, there was no dose- 
response in the time to first ventricular tachycardia or fibrilla- 
tion event for the 24-h double-blind period. The analysis of 
time to first event showed that after hour 2, there was a 
separation between the 500-mg dose group and the two higher 
dose groups. This separation continued to increase and 
reached maximal separation by hour 12 (Fig. 2). The overall 
test for a dose-related trend among the three dose groups was 
not statistically significant (p = 0.305). However, there was a 
significant dose-response in time to first event during the first 
12-h period but not at 24 h (post hoc analysis) between the 
500-rag and the combined 1,000- and 2,000-mg dose group 
(median time 4.8 h vs. >12 h, respectively, p = 0.046). These 
data are shown in Figure 3 and summarized in Table 3. 
A three-dimensional scatter plot of the time of next hypo- 
tensive ventricular tachycardia or fibrillation event as a func- 
tion of time and cumulative dose of intravenous amiodarone 
(loading plus maintenance plus supplemental infusions) is 
shown in Figure 4. At earlier time periods and at lower 
cumulative doses (near the lower right portion of the plot) 
there was a shorter median time of next event. Longer times to 
recurrence were noted during the first 12 to 16 h with higher 
cumulative amiodarone doses and at higher infusion rates. 
After that, the time of next event is largely independent of
cumulative intravenous amiodarone dose or time on therapy, 
irrespective of dosing regimen. 
The assessment by an investigator of the overall condition 
of the patient vis-fi-vis arrhythmia is a pertinent measure of 
overall response. That is, not every episode of ventricular 
tachycardia h s the same clinical significance. The physician is 
subjectively able to synthesize a multitude of factors to deter- 
mine the clinical significance of a breakthrough arrhythmia. 
The rate and frequency of the breakthrough tachycardia events 
and the patient's ability to tolerate the episode must be 
factored into the determination of clinical significance. A
quantitative measure of this determination is the number of 
supplemental infusions given by the investigator (who had no 
knowledge of the patient's assigned ose regimen) to treat 
breakthrough episodes of ventricular tachycardia or fibrilla- 
tion. 
JACC Vol. 27, No. 1 LEVINE ET AL. 71 
January 1996:67-75 AMIODARONE lN UNSTABLE VENTRICULAR TACHYARRHYTHMIAS 
Figure 2. Hourly Kaplan-Meier estimates of the per- 
cent of patients remaining event free. A = amioda- 
rone. 
Percent of Patients 
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The number of supplemental infusions administered uring 
the loading period (hours 0 to 6), when investigators were free 
to administer these supplemental infusions without consider- 
ing treatment ineffective, was analyzed (Table 4). A signifi- 
cantly greater number of supplemental infusions of intrave- 
nous amiodarone (prespecified secondary end point) were 
administered during the loading period in the 500-rag dose 
group than in the 2,000-rag dose group ([mean _+ SE] 1.09 +_ 
1.57 vs. 0.51 + 0.97, p = 0.004), suggesting a dose-response 
relation. These results hold true even after correcting for 
varying lengths of time of therapy because of patient dropout 
by calculating the number of supplemental infusions adminis- 
tered per hour; again, the 500-rag dose group received a 
significantly greater number of boluses than the 2000-rag dose 
group (p = 0.011). Similarly, the total amiodarone dose 
administered during the entire 24-h period as open-label 
supplemental infusions (post hoc analysis) was greater in the 
500-rag dose group than in the 2,000-rag dose group (264.0 _+ 
553.0 vs. 168.1 + 242.7 rag, p = 0.066). Finally, the proportion 
of patients requiring supplemental infusions during the loading 
period (post hoc analysis) was significantly greater in the 
500-rag dose group than in the 2,000-rag roup (47% vs. 29%, 
p = 0.013). 
Relation of other factors to success of intravenous amioda- 
rone therapy. The patient's response to intravenous amioda- 
rone might have been related to the etiology of the heart 
disease and left ventricular dysfunction (predefined secondary 
end point). However, the presence or absence of underlying 
cardiac disease, including coronary artery disease, cardiomy- 
opathy or valvular disease, was not predictive of outcome. The 
Figure 3. Hourly Kaplan-Meier estimates of cumulative per- 
cent of patients remaining event free during the first 12 h after 
initiation of intravenous amiodarone. 
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Figure 4. Three-dimensional scatterplot of median time to next 
ventricular tachycardia or ventricular fibrillation event (z axis) as a 
function of time (y axis) and cumulative dose of intravenous 
amiodarone (x axis). Note that pillar height is proportional to 
number of patients with data at each time period analyzed. 
type of presenting arrhythmia (hypotensive ventricular tachy- 
cardia, ventricular fibrillation or incessant ventricular tachycar- 
dia) or the severity of left ventricular dysfunction had no 
significant influence on the results of the primary efficacy end 
point analysis. 
Safety. Amiodarone-related a verse effects occurred in 
105 patients (38%). The most commonly reported events are 
summarized in Table 5. The frequency of adverse ffects was 
similar across dose groups. Hypotension, the most common 
adverse experience, required vasopressor therapy in 38 pa- 
tients (14%) and led to death in 6 (2%). Bradycardia required 
temporary pacing in only two patients. The incidence of 
abnormal liver function tests did not increase with higher doses 
(2 of 88 patients at the 500-rag dose, 4 of 92 patients at the 
1,000-rag dose, 3 of 93 patients at the 2,000-rag dose, p = 
0.495). 
Six patients (2%) developed proarrhythmia defined as 
new-onset ventricular fibrillation (two patients) or torsade de 
pointes (4 patients). Additional exacerbating factors were 
reported in all six patients, such as acute ischemia or electro- 
lyte imbalances. Four of the six patients were assigned to the 
500-rag dose group, one to the 1,000-mg dose group and one to 
the 2,000-rag dose group. Thirteen patients (5%) had a signif- 
icant increase in corrected QT (QTc) intervals (>0.55 s), and 
38 (14%) had QTc increases ->25% from baseline. However, 
increases in QTc intervals were not dose related, and no 
patient with an increased QTc interval experienced proar- 
rhythmia. 
Overall, congestive heart failure was reported in 48 patients 
(18%): It was preexisting in 39 and new onset in 9. During 
intravenous amiodarone administration, severe, uncompen- 
sated congestive heart failure was observed in five patients: one 
in the 500-mg group and two each in the 1,000- and 2,000-mg 
dose groups. Seventeen patients (6%) died of congestive heart 
failure during the 90-day study, although in only three of these 
patients was the heart failure of new onset. 
Mortality. The entry criteria for the present study required 
patients to have recurrent, sustained, hypotensive ventricular 
tachycardia or fibrillation refractory to standard intravenous 
antiarrhythmic agents. Additionally, many patients were in 
debilitated condition, and their ventricular tachyarrhythmias 
were manifestations of other life-threatening, sometimes ter- 
minal, cardiac and noncardiac disease. Therefore, the mortal- 
ity rate in this trial was high; 52% of patients (n = 143) died 
during the overall 90-day study. Table 6 shows the number of 
deaths by dose group and time period. Within each time 
Table 4. Mean (±SE) Cumulative Dose by Therapy Group 
End Point 
p Value* 
Dose Group Paired 
500 mg (n = 87) 1,000 mg (n - 92) 2,000 mg (n - 92) Overall? L vs. M L vs. H M vs. H 
Double-blind ose 477.6 _+ 160.8 911.9 _+ 283.0 1,753.1 +_ 645.2 0.0001 0.0001 0.0001 0.0001 
No. of supplemental infusions, 0 to 6 h 1.09 _+ 1.57 0.88 _+ 1.38 0.51 -+ 0.97 0.0151 0.2829 0.0043 0.0689 
Supplemental infusion dose 
0-6 h 156.6 _+ 232.2 130.1 _+ 203.3 76.6 -+ 146.7 0.0366 0.3623 0 .0114 0.0987 
0-24 h 264.0 _+ 353.0 263.3 _+ 368.0 168.l _+ 242.7 0.1312 0.8146 0.0662 0.104 
Supplemental infusions/h, 0-6 h 0.24 + 0.43 0.18 _+ 0.31 0.15 _+ 0.52 0.0111 0.2604 0.0031 0.061 
Total dose 741.9 _+ 419.2 1,175.2 ÷ 483.7 1,921.2 _+ 688.8 0.0001 0.0001 0.0001 0.0001 
No. (%,) of pts requiring supplemental infusions 41/87 37/92 27/93 0.042 0.369 0.014 0.124 
(47%) (40%) (29%) 
*Analysis of variance (rank transformed). l'Chi-square statistic. H = high dose group (2,000 rag); L low dose group (500 rag); M = medium dose group 
(1,000 rag); pts = patients. 
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Table 5. Emergent Drug-Related Adverse Events 
Amiodarone Dose Group 
500 mg 1,000 mg 2,000 mg Total 
Adverse Event (n = 88) (n = 92) (n : 93) (n = 273) 
Cardiovascular 
Hypotension 15 (17) 9 (10) 16 (17) 40 (15) 
Bradycardia 5 (6) 3 (3) 6 (6) 14 (5) 
EMD/asystole 5 (6) 3 (3) 4 (4) 12 (4) 
Proarrhythmia 4 (5) 1 (1) 1 (1) 6 (2) 
Congestive heart failure 1 (1) 2 (2) 2 (2) 5 (2) 
Shock 1 (1) 1 (1) 1 (1) 3 (1) 
Noncardiovascular 
Nausea 7 (8) 1 (1) 3 (3) 11 (4) 
Abnormal iver 2 (2) 4 (4) 3 (3) 9 (3) 
function tests 
Fever 1 (1) 2 (2) 4 (4) 7 (3) 
Increased SGPT 0 (0) 0 (0) 6 (6) 6 (2) 
Vomiting 2 (2) 2 (2) 2 (2) 6 (2) 
EMD = electromechanical dissociation; SGPT = serum glutamic pyruvic 
transaminase. Data presented are number (%) of patients. 
period, the death rate did not differ significantly among the 
groups. Table 7 shows the most commonly reported causes of 
death. There were no significant differences among the dose 
groups in either number of deaths at any time period or in the 
primary causes of death. 
D iscuss ion  
Overall, intravenous amiodarone use was associated with 
apparent antiarrhythmic response in -40% of patients meet- 
ing study entry requirements (primary end point). The present 
study failed to demonstrate a dose-response to intravenous 
amiodarone with respect to the proportion of patients who 
survived with a successful response, defined as no further 
episodes of ventricular tachycardia or fibrillation (primary end 
point) and no adverse drug effects during hours 6 to 24, or with 
respect to mortality. However, some of the objective and 
subjective quantitative measures of clinical response did dem- 
onstrate a statistically significant dose-response to intravenous 
amiodarone. 
Table 6. Mortality by Dose Group and Time Period 
No. (%) of Deaths/Dose Group 
500 mg 1,000 mg 2,000 mg p Value 
Time Period (n = 88) (n = 92) (n = 93) (log-rank test) 
Hour 24 16 (18) 17 (18) 14 (15) 0.894 
Double blind 11 (13) 11 (12) 9 (10) 
Open label 5 (6) 6 (7) 7 (8) 
Hour 48 18 (20) 19 (21) 20 (22) 
Day 5 27 (31) 29 (32) 32 (34) 
Day 10 30 (34) 32 (35) 32 (34) 
Day 20 35 (40) 35 (38) 37 (40) 
Day 30 37 (42) 36 (39) 44 (47) 
Total (>day 90) 43 (49) 46 (50) 54 (58) 0.406 
Table 7. Primary Causes of Death by Dose Group 
Dose Groups 
500 mg 1,000 mg 2,000 mg Total 
Primary Causes of Death (n = 88) (n = 92) (n = 93) (n = 273) 
All deaths 43 (48) 46 (50) 54 (58) 143 (52) 
Cardiovascular events 
Refractory HDVT/VF 17 (19) 20 (22) 22 (24) 59 (22) 
Cardiogenic shock 2 (2) 9 (10) 6 (6) 17 (6) 
Cardiac arrest 6 (7) 0 (0) 3 (3) 9 (3) 
Asystole 2 (2) 1 (1) 4 (4) 7 (3) 
Cardiac failure 1 (1) 4 (4) 1 (1) 6 (2) 
Congestive heart failure 2 (2) 2 (2) 2 (2) 6 (2) 
EMD 3 (3) 0 (0) 1 (1) 4 (1) 
Complete heart block 1 (1) 0 (0) 1 (1) 2 (1) 
Myocardial infarction 2 (2) 0 (0) 0 (0) 2 (1) 
Sudden cardiac death I (1) 1 (1) 0 (0) 2 (1) 
Noncardiovascular events 
Sepsis 3 (3) 3 (3) 5 (5) 11 (4) 
Multiple organ failure 0 (0) 3 (3) 1 (1) 4 (1) 
Respiratory failure 2 (1) 0 (0) 1 (1) 3 (1) 
Data presented are number (%) of patients. Abbreviations as in Tables 1 
and 5. 
One hundred ten (46%) of 237 patients who completed the 
6-h loading infusion responded to intravenous amiodarone 
after therapy with lidocaine, procainamide and bretylium 
failed. This result is consistent with reports of others (6-9,11) 
in which 50% to 100% of patients responded to intravenous 
amiodarone. Our results are therefore consistent with those of 
others in this regard. Furthermore, to our knowledge, our 
results represent the largest series of patients studied in a 
prospective manner. 
Both subjective and objective measures of response were 
evaluated. The subjective finding by the investigators of a 
positive effect of intravenous amiodarone on suppression of 
hypotensive sustained ventricular tachyarrhythmias was quan- 
tified by recording the number of supplemental boluses of 
intravenous amiodarone that a patient received (prespecified 
secondary end point). Patients were only to receive additional 
intravenous amiodarone if they had a breakthrough event; yet 
these boluses were not required for every breakthrough event. 
Rather, the boluses were given at the discretion of the inves- 
tigator who had no knowledge of infusion rate and dose group. 
The decision was a clinical one based on the characteristics and 
frequency of the recurrent events, as well as on the stability of 
the patient's condition. Those patients in the 1,000- and 
2,000-rag dose groups received significantly fewer supplemen- 
tal boluses than those in the 500-rag dose group, suggesting a
positive effect of the higher doses on suppression of the most 
clinically significant hypotensive sustained ventricular tachyar- 
rhythmia episodes (Table 4). 
There was also a suggestion that the time to next event 
(post hoc analysis) was related to cumulative amiodarone dose. 
As shown in Figure 4, there was both a dose- and time- 
dependent relation suggested between intravenous amioda- 
rone administration and time to next event. However, these 
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data could not be analyzed statistically because of varying 
sampling frequency among patients. Nonetheless, it appears 
that with increasing dose at any time or with increasing time at 
any dose (Fig. 4, lower right portion), there is an increased 
time to next ventricular tachycardia orfibrillation event, which 
was most apparent during the first 12 h. 
There were trends among treatment groups in the dose- 
response tendencies in the time to first ventricular tachycardia 
or fibrillation events. In the scatterplot f Figure 4, relating 
time to next event o cumulative time and dose, most of the 
cumulative drug effect was observed in the first 12 h, and when 
the first 12 h of therapy were considered, patients receiving the 
1,000- and 2,000-rag dose of intravenous amiodarone had a 
longer time to first event (p = 0.046) than those receiving the 
500-rag dose (Fig. 3). 
The mortality rate of the present group of patients was high, 
as was expected. There was no relation between mortality and 
dose regimen of intravenous amiodarone. Because of ethical 
reasons, no placebo control was used, and supplemental bo- 
luses were allowed. Because more patients in the low dose 
group received boluses than those in the high dose group, 
actual differences in delivered intravenous amiodarone were 
smaller. In addition, the lack of a dose-response may have been 
the result of the very ill but heterogeneous nature of the 
patients tudied. That is, in some patients the ventricular 
arrhythmia was situational rather than the result of severe 
end-stage cardiac disease. In these patients, control of the 
ventricular arrhythmia led to survival; in others, however, the 
arrhythmia was the final common pathway of a failing heart, 
and death occurred even with arrhythmia control. The study 
was not designed to control for these or other factors with 
respect o mortality analysis. 
In addition, we cannot exclude the possibility that some of 
the deaths were due to proarrhythmia. In some cases, refrac- 
tory tachyarrhythmias could have resulted from the amioda- 
rone, whereas in others, they could have been consistent with 
the natural history of the patient. Thus, proarrhythmia was 
defined as new polymorphic ventricular tachyarrhythmias (tor- 
sade de pointes or ventricular fibrillation), but it is acknowl- 
edged that the true proarrhythmia r te may have been under- 
estimated. This underestimation may have also contributed to
the lack of dose-response in the mortality data. 
There were no significant differences among treatment 
groups in the overall time to death. However, we do believe 
that intravenous amiodarone may have had a favorable ffect 
in these patients. The patients enrolled in the present study 
had immediately life-threatening ventricular tachyarrhythmias 
that were refractory to all available drug therapies. Without 
successful therapy, the death rate in patients as ill as these 
would most likely have been much higher than the 24-h 
incidence of 18% found in the present study. 
Study limitations. The borderline significance of the dose- 
response in the time to first hypotensive ventricular tachycar- 
dia or fibrillation event for the 24-h double-blind period (p = 
0.1339) may have been the result of the small sample size in the 
study. The sample size required to detect a statistically signif- 
icant difference (p = 0.05) between the 500- and 2,000-mg dose 
groups can be estimated on the basis of the proportion of 
patients who at least completed the loading infusion and who 
had a successful response from the end of the loading infusion 
to the end of the double-blind period. Thirty-two (41%) of 78 
patients in the 500-mg dose group, 36 (45%) of 80 in the 
1,000-rag dose group and 42 (53%) of 79 in the 2,000-rag dose 
group met these criteria. Using these observations, a sample 
size of 367 patients would have been required to observe a 
difference between groups, assuming a power of 90%. Thus, 
our sample size of 273 patients was insufficient. If additional 
patients had been enrolled, the nearly significant dose-response 
relation oted may have reached statistical significance. 
The lack of a systematic dose-response r lation is also 
consistent with similar benefit or lack of benefit in all three 
groups. The trends as well as the significant findings in the 
secondary end points and post hoc analyses (e.g., number of 
boluses given and time to first event in the first 12 h) suggest 
that there is a dose-response toamiodarone but that the study 
was limited by sample size. 
The present study has other limitations: 1) We were unable 
to perform subset analyses within different diagnostic groups 
(e.g., types of coronary artery disease and cardiomyopathy); 
and 2) the lack of a control group precludes the interpretation 
of findings in terms of the true efficacy or in quantification f
a success rate. Nonetheless, the favorable response to the drug 
is strongly suggested by our data. 
Summary. Intravenous amiodarone use in patients with 
recurrent, refractory, hypotensive ntricular tachyarrhythmias 
is relatively safe and may be associated with a decrease in 
expected mortality in these critically ill patients. Measures of 
drug response, as quantified by the number of supplemental 
intravenous amiodarone boluses given in blinded manner, did 
demonstrate a statistically significant dose-response r lation. 
There was a significant dose-response r lation between the 
500-mg dose group and the combined 1,000- and 2,000-mg 
dose groups in the time to first event when the first 12 h were 
considered (p = 0.046). However, there was no significant 
dose-response r lation in time to first event over 24 h or in 
overall mortality, perhaps because of the insufficient sample 
size of the study or the relative insensitivity of these nd points 
in measuring drug effect in this critically ill cohort. Larger 
studies using lower doses of amiodarone will be required to 
further demonstrate he dose-response relation needed to 
prove drug efficacy. 
Appendix 
Amiodarone Intravenous Multicenter Trial Group: 
List of Principal Investigators 
David G. Benditt, MD, University of Minnesota Hospitals, Minneapolis, 
Minnesota. David S. Cannom, MD, Good Samaritan Medical Center, Los 
Angeles, California. Don Chilson, MD, Deaconess Medical Center, Spokane, 
Washington. James Foster, MD, University of North Carolina, Chapel Hill, 
North Carolina. Jay Franklin, MD, Baylor Medical Center, Dallas, Texas. Ted 
Friehling, MD, Fairfax Hospital, Fairfax, Virginia. Frank Gold, MD, Proctor 
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Hospital, Peoria, Illinois. J. Anthony Gomes, MD, The Mount Sinai Medical 
Center, New York, New York. Mitchell Greenspan, MD, Life Mark Medical 
Center, Sellersville, Pennsylvania. Lawrence Griflith, MD, The Johns Hopkins 
Hospital, Baltimore, Maryland. Arthur Hagan, MD, Tulsa Heart Center, Tulsa, 
Oklahoma. Leonard Horowitz, MD, Presbyterian Medical Center, Philadelphia, 
Pennsylvania. S K. Stephen Huang, MD, University of Massachussets Medical 
Center, Worcester, Massachussets. Warren M. Jaelunan, MD, University of 
Oklahoma Health Science Center, Oklahoma City, Oklahoma. Nicholas Z. 
Kerin, MD, Sinai Hospital of Detroit, Detroit, Michigan. Richard Klein, MD, 
Veterans Affairs Medical Center, Albuquerque, New Mexico. Peter Kowey, MD, 
The Lankenau Hospital, Wynnewood, Pennsylvania. Peter KudenchuL MD, 
University of Washington Medical Center, Seattle, Washington. Michael H. 
Lehmann, MD, Harper Hospital, Detroit, Michigan. Joseph H. Levine, MD, St. 
Francis Hospital, Roslyn, New York. Bruce D. Lindsay, MD, Barnes Hospital, St. 
Louis, Missouri. Frank Marcus, MD, University of Arizona Medical Center, 
Tucson, Arizona. Ali Massumi, MD, Texas Medical Center, St. Luke's Episcopal 
Hospital, Houston, Texas. Syed Mohiuddin, MD, Creighton Cardiac Center, 
Omaha, Nebraska. Fred Morady, MD, University of Michigan Hospitals, Ann 
Arbor, Michigan. Victor A. Morant, MD, The Cleveland Clinic, Cleveland, Ohio. 
Joel Morganroth, MD, Graduate Hospital, Philadelphia, Pennsylvania. Nelson 
Mostow, MD, MetroHealth Medical Center, Cleveland, Ohio. R. Joe Noble, MD, 
St. Vincent Research Center, Indianapolis, Indiana. Antonio Pacifico, MD, The 
Methodist Hospital, Houston, Texas. Edward V. Platia, MD, Washington 
Hospital Center, Washington, D.C. Marc L. Piatt, MD, Torrance Memorial 
Hospital, Torrance, California. Dan Rodeu, MD, Vanderbilt University Medical 
Center, Nashville, Tennessee. Melvin Scheinman, MD, University of California 
Medical Center, San Francisco, California. Jesus E. Val Mejias, MD, Wichita 
Institute for Clinical Research, Wichita, Kansas. John R. Windle, MD, University 
of Nebraska Medical Center, Omaha, Nebraska. Roger Winkle, MD, Sequoia 
Hospital, Redwood City, California. Raymond L Woosley, MD, PhD, George- 
town University, Washington, D.C. Douglas Zipes, MD, Krannert Institute of 
Cardiology, Indianapolis, Indiana. 
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